GPR27 Antibody

What is GPR27 and what are its main biological functions?

GPR27 (G-protein coupled receptor 27, also known as SREB1 or Super conserved receptor expressed in brain 1) is a highly conserved orphan G protein-coupled receptor with a molecular weight of approximately 39 kDa. It functions primarily in:

• Pancreatic beta cell insulin transcription and glucose-stimulated insulin secretion

• Immune cell interactions, with significant expression in macrophages as revealed by single-cell analysis

• Potential tumor suppression in gastric cancer, as lower expression correlates with better patient outcomes

Which detection techniques are compatible with commercial GPR27 antibodies?

Current commercial GPR27 antibodies can be utilized in multiple experimental techniques with the following recommended dilutions:

For optimal results in immunohistochemistry, researchers have reported success using anti-GPR27 protein antibody at 1:300 dilution (as used in gastric cancer studies) with standard antigen retrieval using citrate buffer (pH 6.0) .

What species reactivity can be expected from commercial GPR27 antibodies?

Commercial GPR27 antibodies typically demonstrate cross-reactivity with multiple species due to the highly conserved nature of this receptor. Current antibodies show confirmed reactivity with:

• Human GPR27

• Mouse GPR27

• Rat GPR27

When working with less common model organisms, preliminary validation is strongly recommended as sequence homology varies. The high conservation of GPR27 across species makes many antibodies suitable for comparative studies, though epitope-specific variations may affect binding affinity.

What are the recommended storage conditions for GPR27 antibodies?

For optimal stability and performance:

• Store at -20°C for long-term storage

• Avoid repeated freeze-thaw cycles (aliquot upon receipt)

• Ship on wet ice during transport

• Store working dilutions at 4°C for up to one week

• Use buffered aqueous solutions with stabilizing proteins (typical concentration ~1 mg/mL)

Most commercial antibodies come in buffered aqueous solutions that maintain stability, but proper storage conditions are essential to prevent degradation and maintain consistent experimental results.

How can I validate GPR27 antibody specificity for my experimental models?

Comprehensive validation requires a multi-method approach:

• Positive and negative tissue controls: Compare tissues known to express GPR27 (pancreatic islets, specific immune cell populations) against those with minimal expression.

• Knockout validation: Ideally, tissues from GPR27 knockout models should be used as negative controls. Published knockout mouse models have demonstrated complete absence of GPR27 expression while maintaining normal development .

• Peptide competition assay: Pre-incubate the antibody with immunizing peptide before application to validate binding specificity.

• Multiple antibody comparison: Use antibodies recognizing different epitopes of GPR27 to confirm localization patterns.

• Correlation with mRNA expression: Validate protein expression patterns against mRNA data from techniques like qPCR or RNA-seq.

For gastric cancer research specifically, comparing normal gastric mucosa with tumor tissue provides an internal validation control as differential expression has been documented in multiple studies .

What are the challenges in detecting GPR27 in immune cells and how can they be overcome?

Detection of GPR27 in immune cells presents several technical challenges:

• Cell-specific expression levels: Single-cell analysis has revealed that GPR27 is primarily expressed in macrophages but at varying levels depending on activation state .

• Recommended approach for macrophage studies:

  • Use cell sorting (FACS) to obtain pure macrophage populations

  • Compare different macrophage polarization states (M1 vs M2)

  • Include multiple macrophage markers (CD68, CD163) in co-staining experiments

  • Consider tissue-specific macrophage phenotypes when interpreting results

• Signal amplification techniques: For low-expressing cells, consider:

  • Tyramide signal amplification for immunohistochemistry

  • More sensitive detection systems for western blotting (e.g., chemiluminescent substrates with longer exposure times)

  • Increased antibody concentration with extended incubation periods

• Controls for non-specific binding: Include isotype controls and FcR blocking reagents when staining immune cells to minimize background.

What methodological considerations are important when using GPR27 antibodies for cancer research?

Based on recent gastric cancer studies, several methodological considerations are critical:

• Tissue processing and antigen retrieval optimization:

  • Heat-induced epitope retrieval using citrate buffer (pH 6.0) for 20 minutes has proven effective for GPR27 detection

  • Overnight incubation with primary antibody at 4°C improves specific staining

• Quantification methodology:

  • Implement a semi-quantitative scoring system accounting for both staining intensity (0-3) and staining scope (1-4 points based on percentage of positive cells)

  • Final scores should be calculated by multiplying intensity and scope scores

  • Consider digital image analysis for more objective quantification

• Correlation with clinical parameters:

  • GPR27 expression correlates with tumor mutational burden (TMB) - include TMB analysis in study design

  • GPR27 methylation status significantly affects expression - consider parallel methylation analysis

• Subcellular localization considerations:

  • Positive staining for GPR27 protein is primarily observed in the cytoplasm of gastric cancer cells

  • Membrane versus cytoplasmic localization should be documented separately

How should researchers interpret conflicting data between GPR27 mRNA and protein expression levels?

Discrepancies between mRNA and protein expression are common with GPR27 and require careful interpretation:

• Methylation effects: GPR27 exhibits significant regulation by promoter methylation. There is a strong inverse correlation (r=-0.64, P<0.0001) between GPR27 promoter methylation and GPR27 transcription in gastric cancer . Consider parallel methylation analysis using:

  • Bisulfite sequencing of the promoter region

  • Methylation-specific PCR

  • Analysis of specific CpG sites (particularly cg22823146, which shows the strongest correlation with expression)

• Post-transcriptional regulation: Consider analyzing:

  • miRNA regulation (several miRNAs are predicted to target GPR27)

  • mRNA stability assays

  • Translation efficiency

• Protein stability factors: Examine:

  • Proteasomal degradation pathways

  • Post-translational modifications affecting stability

  • Trafficking defects that may affect antibody accessibility to epitopes

• Technical considerations:

  • Different antibodies may recognize different protein conformations or isoforms

  • Sample preparation methods may affect epitope availability

  • RNA preservation quality may differ from protein preservation in the same samples

What are the implications of GPR27's relationship with immune infiltration for immunotherapy research?

Recent findings on GPR27's relationship with immune cell infiltration open new research directions:

• Correlation with immune cell populations: GPR27 expression shows significant correlations with immune cell infiltration patterns in gastric cancer. Researchers should consider:

  • Analyzing relationships between GPR27 expression and specific immune cell subsets (T cells, macrophages, dendritic cells)

  • Evaluating expression changes in response to immunotherapy treatments

  • Investigating potential predictive value for immunotherapy response

• Macrophage-specific expression: Since single-cell analysis has shown that GPR27 is mainly expressed in macrophages, studies should:

  • Characterize GPR27 expression in different macrophage polarization states (M1 vs M2)

  • Investigate whether GPR27 influences macrophage function in the tumor microenvironment

  • Explore GPR27 as a potential target for macrophage-directed therapies

• Integration with immune checkpoint molecules: Research should examine:

  • Correlation between GPR27 expression and established immune checkpoint molecules (PD-1, PD-L1, CTLA-4)

  • Potential synergistic effects of targeting GPR27 alongside established checkpoint inhibitors

  • Changes in GPR27 expression in response to checkpoint inhibitor treatment

A comprehensive experimental approach would include multiplexed immunofluorescence to simultaneously visualize GPR27 and immune cell markers in tissue sections.

How can researchers accurately assess GPR27's role in insulin regulation using GPR27 antibodies?

Based on knockout mouse studies, GPR27 influences insulin regulation in complex ways that require careful experimental design:

• Comprehensive phenotyping approach:

  • Measure both insulin mRNA (which decreases by approximately 30% in knockouts) and protein content (which remains relatively unchanged)

  • Evaluate both basal and glucose-stimulated insulin secretion

  • Assess beta cell mass and morphology alongside molecular markers

• Gene-expression correlation studies:

  • Examine relationship with Pdx1 expression, which is reduced in GPR27 knockout islets

  • Consider effects on neighboring genes like Eif4e3, which can be affected by GPR27 deletion

• Experimental design considerations:

  • Include both in vitro (isolated islets) and in vivo (glucose tolerance tests) assessments

  • Account for potential compensatory mechanisms in chronic knockout models

  • Consider inducible knockout systems to distinguish developmental from acute effects

• Technical recommendations for pancreatic studies:

  • Use specialized fixation protocols for pancreatic tissue to preserve antigenicity

  • Co-stain with insulin and other beta cell markers for proper identification

  • Consider optical clearing techniques for 3D visualization of islet architecture

What novel experimental approaches could advance our understanding of GPR27 signaling mechanisms?

Several cutting-edge approaches could significantly advance GPR27 research:

• Proximity labeling techniques: Methods such as BioID or APEX2 fused to GPR27 could identify proximal interacting proteins in living cells, revealing signaling complex components.

• CRISPR-based screening: Genome-wide or targeted CRISPR screens could identify genes that modify GPR27 function or expression, particularly in:

  • Insulin regulation pathways

  • Cancer cell survival and proliferation

  • Immune cell function

• Single-cell multi-omics approaches: Integration of:

  • Single-cell RNA sequencing

  • Single-cell proteomics

  • Spatial transcriptomics

  This would provide comprehensive understanding of cell-type specific GPR27 functions and regulation.

• Development of selective GPR27 modulators: As an orphan receptor, identification of endogenous ligands or development of selective modulators remains a critical research need.

• Structural biology approaches: Cryo-EM or X-ray crystallography of GPR27 would provide insights into:

  • Potential ligand binding sites

  • Conformational changes associated with activation

  • Structure-based drug design opportunities

How should researchers integrate GPR27 methylation analysis with antibody-based protein detection?

Given the significant inverse correlation between GPR27 methylation and expression, an integrated approach is recommended:

• Key methylation sites to analyze:

  • cg03024619 shows the most significant prognostic value (HR=0.553, P<0.0001)

  • cg22823146 exhibits the strongest correlation with mRNA expression (r=-0.6639, P<0.0001)

• Integrated analysis workflow:

  • Perform bisulfite sequencing or methylation array analysis of the GPR27 promoter

  • Correlate methylation patterns with mRNA expression using qPCR

  • Validate protein expression using immunohistochemistry or western blotting

  • Integrate all three data types for comprehensive understanding

• Experimental considerations:

  • Use matched samples for all analyses to enable direct correlations

  • Consider cell type heterogeneity when analyzing bulk tissue samples

  • Validate findings in independent cohorts

• Data integration approaches:

  • Multivariate statistical modeling

  • Machine learning approaches for pattern recognition

  • Network analysis incorporating methylation, expression, and clinical data

What are the considerations for developing therapeutic approaches targeting GPR27?

Based on current research, several aspects should be considered for therapeutic development:

• Potential therapeutic contexts:

  • Cancer immunotherapy: Given GPR27's expression in macrophages and correlation with immune infiltration

  • Metabolic disorders: Based on its role in insulin regulation

• Target validation approaches:

  • Tissue-specific conditional knockout models

  • Inducible expression systems

  • Selective pharmacological tools (when available)

• Biomarker development considerations:

  • GPR27 methylation status may serve as a prognostic biomarker in gastric cancer

  • Protein expression patterns in specific immune cell populations may predict treatment response

  • Combined analysis with other markers will likely provide superior predictive value

• Delivery considerations for nucleic acid therapeutics:

  • Cell-type specific targeting strategies

  • Consideration of tissue barriers (particularly for pancreatic targeting)

  • Potential off-target effects on neighboring genes like Eif4e3

• Therapeutic antibody development:

  • Identification of accessible epitopes in native conformation

  • Consideration of internalization dynamics

  • Evaluation of potential for antibody-dependent cellular cytotoxicity in cancer contexts